Home > Healthcare > Pharmaceuticals > Finished Drug Form > Biological Skin Substitutes Market

Biological Skin Substitutes Market Share

Report ID: GMI6964
Published Date: Oct 2023
Report Format: PDF

Download Free Sample

Biological Skin Substitutes Market Share

The biological skin substitutes industry is consolidated, with major players such as Mylan N.V., Misonix, Inc., and others dominating the market. These companies are focused on continuous product innovation to secure a significant market share. For instance, Misonix is known for its Theraskin product, which is a biosynthetic skin substitute that combines synthetic materials with biological components to promote wound healing.

Some of the eminent market participants operating in the biological skin substitutes industry include:

Organogenesis Inc
Smith & Nephew plc
MiMedx Group, Inc.
Misonix, Inc. (Bioventus)
Avita Medical
Stratatech Corporation (Mallinckrodt Pharmaceuticals)
BioTissue
Aroa Biosurgery
ProgenaCare
Mimedx Group (MiMedx Group, Inc.)
Tissue Regenix
Stryker
Vericel Corporation
Integra LifeSciences

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Biological skin substitutes industry size reached USD 287 million in 2022 and is estimated to record USD 640 million by 2032 due to higher adoption for replacing or regenerating damaged or lost skin tissue

The human donor tissue-derived products segment reached USD 188 million in 2022 attributed to advantages, such as exceptional biological compatibility, proven safety record, and established efficacy.

The acute wounds application segment accounted for over 59% share of the biological skin substitutes market in 2022 owing to advantages, such as higher incidence, immediate treatment requirements, and positive clinical outcomes.

Demand for biological skin substitutes in the U.S. reached USD 109 million in 2022 and is predicted to witness substantial growth through 2032 attributed to the annual increase in burn injuries in the nation